This page provides a comprehensive comparison of three major neurodegenerative dementias: Dementia with Lewy Bodies (DLB), Parkinson's Disease (PD), and Alzheimer's Disease (AD). While these disorders share some pathological features, they have distinct clinical presentations, biomarker profiles, and treatment approaches.
| Feature | Dementia with Lewy Bodies | Parkinson's Disease | Alzheimer's Disease |
|---|---|---|---|
| Primary Protein Pathology | Alpha-synuclein | Alpha-synuclein | Amyloid-beta, Tau |
| Key Inclusion Bodies | Lewy bodies, Lewy neurites | Lewy bodies, Lewy neurites | Amyloid plaques, neurofibrillary tangles |
| Onset Age | 50-80 years (mean ~75) | 50-80 years (mean ~65) | Typically >65 years |
| Prevalence | ~5% of dementia cases | ~1 million (USA) | ~6 million (USA) |
| Core Clinical Features | Visual hallucinations, fluctuating cognition, parkinsonism, RBD | Resting tremor, bradykinesia, rigidity, postural instability | Memory loss, cognitive decline |
| Cognitive Profile | Executive dysfunction, visuospatial deficits, fluctuating cognition | Executive dysfunction, later dementia | Memory encoding loss, progressive cognitive decline |
| Motor Symptoms | Present (50-70%), moderate | Core feature (100%), progressive | Late stage only |
| Disease Duration | 5-7 years average | 10-15 years average | 8-12 years average |
Both DLB and PD are classified as synucleinopathies characterized by abnormal accumulation of misfolded alpha-synuclein protein. The formation of Lewy bodies represents a common pathological endpoint:
Tau pathology is a feature of all three diseases, though with different patterns:
| Feature | DLB | PD | AD |
|---|---|---|---|
| Cognitive Fluctuation | Core (70-90%) | Variable | Rare |
| Visual Hallucinations | Core (60-80%) | Late (30-50%) | Late (10-20%) |
| Parkinsonism | Core (50-70%) | Core (100%) | Late (rare) |
| REM Sleep Behavior Disorder | Very common (60-80%) | Very common (50-70%) | Uncommon |
| Memory Loss | Early (retrieval) | Variable | Early (encoding) |
Dementia with Lewy Bodies:
Parkinson's Disease:
Alzheimer's Disease:
| Feature | DLB | PD | AD |
|---|---|---|---|
| Bradykinesia | Common (50-70%) | Core (100%) | Rare, late |
| Resting Tremor | Less prominent | Core (70-90%) | Rare |
| Rigidity | Common | Core (80-90%) | Rare |
| Postural Instability | Common (late) | Common (50-70%) | Rare, late |
| Onset Pattern | Variable | Typically asymmetric | Symmetric |
| Symptom | DLB | PD | AD |
|---|---|---|---|
| Olfactory Dysfunction | Common | Core feature (>90%) | Common |
| Autonomic Dysfunction | Common (50-60%) | Common (30-50%) | Variable |
| Depression | Common (30-50%) | Common (30-50%) | Common (20-40%) |
| Psychosis | Core feature | Late feature | Late feature |
| REM Sleep Behavior Disorder | Very common | Very common | Uncommon |
| Modality | DLB | PD | AD |
|---|---|---|---|
| DaT-SPECT | Reduced striatal uptake | Reduced striatal uptake | Usually normal |
| FDG-PET | Occipital hypometabolism | Variable | Posterior cingulate, temporoparietal hypometabolism |
| MRI | Relative hippocampal preservation | Usually normal | Hippocampal atrophy |
| Amyloid PET | Variable (50% positive) | Usually negative | Positive |
| Biomarker | DLB | PD | AD |
|---|---|---|---|
| Alpha-synuclein (seed amplification) | Positive | Positive | Negative |
| Total Tau | Elevated | Normal | Elevated |
| Phosphorylated Tau | Normal | Normal | Elevated |
| Amyloid-beta 1-42 | Normal or reduced | Normal | Reduced |
| Neurofilament Light Chain (NfL) | Elevated | Elevated | Elevated |
| Feature | DLB | PD | AD |
|---|---|---|---|
| Primary Inclusions | Lewy bodies (cortical) | Lewy bodies (brainstem > cortical) | amyloid plaques, NFT |
| Staging System | Braak α-syn (I-VI) | Braak α-syn (I-VI) | Braak NFT (I-VI), Thal amyloid |
| Neuronal Loss | Substantia nigra, locus coeruleus | Substantia nigra (prominent) | Hippocampus, cortex |
| Comorbid Pathology | Common (30-50% AD) | Common (up to 50% AD in PDD) | Primary |
| Treatment | DLB | PD | AD |
|---|---|---|---|
| Cholinesterase Inhibitors | First-line (cognitive) | Limited | First-line |
| Memantine | May be used | Not used | First-line |
| Levodopa/Carbidopa | May help parkinsonism | First-line | Not indicated |
| Dopamine Agonists | Use with caution | First-line | Not indicated |
| Antipsychotics | Severe sensitivity | Use with caution | Use with caution |
DLB:
PD:
AD:
| Gene | DLB Risk | PD Risk | AD Risk |
|---|---|---|---|
| SNCA | Increased | Increased (causative) | No |
| GBA | Increased | Increased | No |
| LRRK2 | Increased | Increased (causative) | No |
| APOE ε4 | Increased | No | Strongly increased |
| MAPT | Increased | Increased | No effect |
| C9orf72 | Rare | Rare | Rare |
| Phase | DLB | PD | AD |
|---|---|---|---|
| Prodromal | RBD, hyposmia, depression | RBD, hyposmia, depression | Subjective cognitive decline |
| Early | Cognitive + motor symptoms | Motor symptoms | MCI |
| Middle | Progressive cognitive decline | Motor complications | Progressive memory loss |
| Late | Severe disability | Severe motor/cognitive | Severe cognitive/functional decline |
While DLB, PD, and AD all represent neurodegenerative diseases with significant clinical impact, they differ in fundamental ways:
Understanding these distinctions is critical for accurate diagnosis, prognostic counseling, and appropriate therapeutic management.